About HizentraInitiating HizentraAssistance and SupportSHARE Nurse Training and ExamInfusion Support CenterProfessional ResourcesFrequently Asked QuestionsHizentra FAQsInfusion FAQsFinancial FAQsPatient Care FAQsSHARE Training FAQsRequest More InformationImportant Safety Information

Infusion FAQs

How many infusion sites are there?
Recommended infusion sites include the thighs, upper arms, stomach, and hips. A Hizentra dose may be infused into multiple injection sites, but no more than 4 sites may be used during 1 infusion.

How long does it take to infuse?
Because Hizentra is a 20% Ig solution, infusion times are short (in the clinical trial, the median duration ranged from 1.6 to 2 hours).

What infusion equipment is needed?
In a clinical trial of Hizentra, the Crono pump and bifurcated MarCal administration set were used.6 For a complete list of items needed for self-administration, please click here. Note that CSL Behring does not endorse specific equipment.

How quickly can you infuse Hizentra?
For the first infusion of Hizentra, the recommended maximum flow rate is 15 mL per hour per site. For subsequent infusions, the flow rate may be increased to a maximum of 25 mL per hour per site as tolerated. However, the maximum flow rate is not to exceed a total of 50 mL per hour for all sites combined at any time. A Hizentra dose may be infused into multiple injection sites, but no more than 4 during the same infusion.

How does a fast infusion rate offered by Hizentra benefit my patients?
Because Hizentra has a fast infusion rate, your patients can spend less time infusing and more time getting on with their lives.

What should my patients expect from infusion with Hizentra?
In the clinical trial (n=49), most adverse reactions (ARs) reported were nonserious. The most common ARs, observed in ≥5% of study subjects, were local injection-site reactions, headache, vomiting, pain, and fatigue.

Injection-site reactions were primarily mild (93.4%) or moderate (6.3%). These are to be expected. Symptoms can include edema, erythema, local heat, local pain, and itching. In moderate cases, the affected area can be tender and larger than a half dollar.5

Can my patients self-administer Hizentra?
Yes, most patients can infuse on their own. However, this should take place only after a patient goes through training and performs a successful return demonstration in front of a healthcare professional.5

Develop an infusion plan that is individualized for each of your patients, including a review of the "Information for Patients" included in the full Prescribing Information for Hizentra5,9

Direct your patients to watch the Hizentra self-administration video.

How is the dose titrated?
The dose of Hizentra should be individualized based on the patient's clinical response to therapy and serum immunoglobulin G (IgG) trough levels.

Begin treatment with Hizentra 1 week after the patient's last IVIg infusion. Prior to switching treatment from IVIg to Hizentra, obtain the patient's serum IgG trough level to guide subsequent dose adjustments.

Establish the initial weekly dose of Hizentra by converting the monthly IVIg dose into a weekly equivalent and increasing it using the dose adjustment factor below. The goal is to achieve a systemic serum IgG exposure (area under the concentration-time curve [AUC]) not inferior to that of the previous IVIg treatment.

Initial recommended weekly dose
To calculate the initial weekly dose of Hizentra, multiply the previous IVIg dose in grams by the dose adjustment factor of 1.53; then divide this by the number of weeks between doses during the patient's IVIg treatment (i.e., 3 or 4).

To convert the Hizentra dose (in grams) to milliliters (mL), multiply the calculated dose (in grams) by 5.

An easy way to calculate this is to use the Hizentra dosage calculator.

Important Safety Information

Immune Globulin Subcutaneous (Human), Hizentra®, is indicated as replacement therapy for patients with primary humoral immunodeficiency (PI), age 2 and older. This includes but is not limited to the humoral immune defect in congenital agammaglobulinemia, common variable immunodeficiency, X-linked agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.

Hizentra is contraindicated in patients with a history of anaphylactic or severe systemic reaction to human immune globulin preparations or components of Hizentra, such as polysorbate 80. Because it contains the stabilizer L-proline, Hizentra is contraindicated in patients with hyperprolinemia. Hizentra is also contraindicated in patients with immunoglobulin A deficiency who have antibodies against IgA and a history of hypersensitivity.

Hizentra should be administered subcutaneously only. Do not administer intravenously.

IgA-deficient patients with anti-IgA antibodies may be at greater risk of developing potentially severe hypersensitivity and anaphylactic reactions with administration of Hizentra. If hypersensitivity occurs or anaphylactic reactions are suspected, discontinue administration immediately and treat as medically appropriate.

Hizentra is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

The most common drug-related adverse reactions (observed in 5% or more of study subjects receiving Hizentra) were local reactions (ie, swelling, redness, heat, pain, and itching at the injection site), headache, diarrhea, fatigue, back pain, nausea, extremity pain, cough, rash, pruritis, vomiting, upper abdominal pain, pain, and migraine.

Monitor patients for thrombotic events and aseptic meningitis (AMS), which have been reported with SCIg. Also look forreactions reported to occur with IVIg treatment that might also occur with Hizentra, including renal dysfunction/failure, hemolysis, and transfusion-related acute lung injury (TRALI).

Ig administration can transiently impair the efficacy of live attenuated virus vaccines, such as measles, mumps and rubella. It can also lead to misinterpretation of serologic testing.

Please see full prescribing information for Hizentra.